Fig. 2From: An ex-ante cost-utility analysis of the deemed consent legislation compared to expressed consent for kidney transplantations in Nova ScotiaResponsiveness of ICUR to changes in the proportion of deceased donor kidney transplantations per year. ICUR incremental cost-utility ratio, ESKD end-stage kidney disease, KT kidney transplantation, QALY quality-adjusted life-yearBack to article page